Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Adipose-derived mesenchymal stem cells for secondary progressive multiple sclerosis
IRCT20091127002778N1Phase 2Completed
- Sponsor
- Mashhad University of Medical Sciences
- Start
- Aug 2016
- Modality
- Stem Cell Therapies → Cell Therapies
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of autologous adipose-derived mesenchymal stromal cells in multiple sclerosis (MS) and secondary-progressive multiple sclerosis (SPMS), sponsored by Mashhad University of Medical Sciences. Primary endpoints: MRI-based neurophysiological efficacy at 9 months, Clinical efficacy by disability assessment at 9 months and 2 more. Started Aug 2016; status: completed.
02
Drugs
autologous adipose-derived mesenchymal stromal cells
03
Conditions
multiple sclerosis (MS)secondary-progressive multiple sclerosis (SPMS)
Beyond the preview
Go deeper on IRCT20091127002778N1.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on IRCT20091127002778N1.